|
Postinor-2
ACTIVE SUBSTANCE
0.75mg levonorgestrel in each tablet.
Other ingredients: silica colloidal anhydrous, magnesium stearate, potato
starch, talc, maize starch, lactose monohydrate.
ACTION
Levonorgestrel is a progestogen inhibiting the implantation of the ovum into
the endometrium, stimulating the motility of the oviduct and increasing the
viscosity of the cervical mucus.
When taken in the middle of the menstrual cycle, the preparation may inhibit
ovulation.
INDICATION
Postinor-2 tablet is an emergency contraceptive preparation that can prevent
conception if it is taken within 72 hours following unprotected intercourse.
The administration of Postinor-2 as an emergency contraceptive is
recommended in the following cases
• if no contraceptive measure of any kind was taken during intercourse,
• if the applied contraceptive measure cannot be considered reliable, i.e.:
- tear or slip or inappropriate use of condom,
- disposition or tear or premature removal of diaphragm or pessary,
- unsuccessfully interrupted coitus,
- erroneous calculation of fertile days in case of periodic abstinence,
- in case of IUD loss or removal,
- omitting the ingestion of 3 or more hormonal contraceptive tablets to
be taken regularly,
• rape.
CONTRAINDICATIONS
Except for existing pregnancy, there are no other absolute medical
contraindications for the administration of Postinor-2 tablet. In case of
vaginal bleeding of unknown origin, hepatic and biliary disease, history of
gestational jaundice, breast, ovarian or uterine carcinoma, it should be
administered after careful consideration of the risk/benefit ratio (unwanted
pregnancy/abortion).
DOSAGE
One Postinor-2 tablet should be ingested within 72 hours following
intercourse and another one 12 hours after taking the first tablet.
According to data of clinical studies, it is advisable to take the first
tablet within 48 hours (but not later than 72 hours) after intercourse,
since the efficacy of the preparation decreases if more than 48 hours elapse
between intercourse and drug ingestion. Postinor-2 tablet may be used at any
time within the menstrual cycle.
If vomiting occurs within 2 hours after drug intake, the dose must be
repeated.
SIDE EFFECTS
Nausea: it occurs in approximately 25% of users.
Vomiting: in 5%
Bleeding disturbances: in some cases, 2-3 days following tablet ingestion
breakthrough or withdrawal bleeding may occur that generally ceases
spontaneously. In the majority of cases the next period starts as expected
or somewhat earlier. If the period is more than 7 days late it is
recommended to perform a pregnancy test.
In case of prolonged or heavy bleeding, gynaecological examination is
advised.
Other side-effects: breast tenderness, headache, dizziness, fatigue.
DRUG INTERACTIONS
Concomitant use of ampicillin, rifampicin, chloramphenicol, neomycin,
sulphonamides, tetracyclines, barbiturates and phenylbutazone may reduce the
contraceptive effect.
WARNING
Use with utmost care in case of asthma, heart failure, hypertension,
migraine, epilepsy, renal impairment, diabetes mellitus, hyperlipidaemia,
depression and in case of existing or former thrombophlebitis,
thromboembolic diseases or stroke.
The preparation may be used exclusively in the above mentioned emergency
cases; it is not appropriate for regular use.
STORAGE
Protected from humidity, at a temperature between 15-30°C.
PACKAGE
2 tablets in a blister. 1 blister in an inner carton. 5 inner carton in a
box.
|
